

Disease

Gene Rearrangement

Translocation

Mutations

Recommended Primary Test

Recommended Secondary Test

IGH
(V_H-J_H)

IGH
(D_H-J_H)

IGK

IGL

IGHV
SHM

TRB

TRD

TRG

IGH-
BCL1
(CCND1)

IGH-
BCL2

BCR-
ABL1*

PML
RARA*

FLT3

NPM1

Lymphoid/ Lymphoma

Myeloid

Marginal Zone Lymphoma (MZL), extranodal^{12,13,27}

88%

58%

84%

29%

23%

10%

16%

Marginal Zone Lymphoma (MZL), nodal¹³

100%

30%

80%

30%

10%

20%

10%

Mantle Cell Lymphoma (MCL)^{2,6,7,12,13,27,37}

100%

11%

100%

44%

*

9%

4%

11%

75%

Follicular Lymphoma (FL)^{3,7,12,13,27,28}

84%

19%

84%

21%

6%

5%

2%

90%

Diffuse Large B-cell Lymphoma (DLBCL)^{3,12,13,27}

80%

30%

80%

28%

21%

14%

15%

30%

Multiple Myeloma (MM) and other Plasma Cell Neoplasms (PCN)^{2,9,10,20,25}

84%

60%

57%

97%

20%

Chronic Lymphocytic Leukemia (CLL)^{11,12,13,15,23,27,35}

100%

43%

100%

30%

*

25%

12%

18%

B-cell Acute Lymphoblastic Leukemia (B-ALL)^{4,12,14,19,21,22,27,29,30,31,32,33,34}

96%

57%

95%

20%

81%

86%

75%

30%

Suspect B-cell Proliferations^{12,26,27,33}

93%

93%

90%

40%

20%

20%

Peripheral T-cell Lymphoma (PTCL)^{12,13,14,24}

35%

4%

2%

98%

94%

T-cell Acute Lymphoblastic Leukemia (T-ALL)^{12,14,21,22,29,31}

24%

25%

4%

92%

68%

95%

Angioimmunoblastic T-cell Lymphoma (AITL)^{12,13,14}

19%

11%

30%

5%

99%

35%

92%

Adult T-cell Leukemia/Lymphoma³⁹

97%

96%

Anaplastic Large-Cell Lymphoma (ALCL)^{12,13,14}

74%

12%

74%

T-cell Prolymphocytic Leukemia (T-PLL)^{12,13,14}

3%

3%

3%

3%

100%

6%

94%

T-cell Large Granular Lymphocytic Leukemia (T-LGL Leukemia)^{12,13,14}

4%

4%

97%

29%

96%

Suspect T-Cell Proliferations^{12,26,40}

10%

10%

90%

11%

90%

Acute Myeloid Leukemia (AML)^{8,16}

33%

64%

Acute Promyelocytic Leukemia (APL)^{1,5,16,17}

90%

Chronic Myeloid Leukemia (CML)^{7,18,19,21,38}

PCR-based Ig/TCR Profiles with Combined Target Prevalence²⁶

	n =	IGH (V _H -J _H)	IGK	IGH + IGK	TCRB	TCRG	TCRB + TCRG
MCL	54	100%	100%	100%	9%	11%	NE
CLL/SLL	56	100%	100%	100%	25%	18%	NE
FL	109	86%	84%	100%	6%	2%	NE
MZL*	41	95%	83%	100%	24%	15%	NE
DLBCL	109	85%	80%	98%	21%	15%	NE
T-PLL	33	9%	3%	NE	100%	94%	100%
T-LGL	28	0%	4%	NE	96%	96%	100%
PTCL-NOS	47	9%	2%	NE	98%	94%	100%
AIT	37	30%	19%	NE	89%	92%	95%
ALCL [‡]	43	2%	0%	NE	74% [‡]	74% [‡]	79% [‡]

*MZL comprises both extranodal (31) and nodal (10) cases.

[‡]The lower percentages in ALCL are partly caused by a series of nine null-type ALCL without any TCR gene rearrangements.

References

- Kakizuka, A et al. (1991) *Cell*, 66:675-684.
- Rimokh, R et al. (1994) *Blood*, 83:1871-1875.
- Gribben, JG et al. (1994) *Blood*, 83:3800-3807.
- Radich, JP et al. (1994) *Leukemia*, 8:1688-1695.
- Gallagher, RE et al. (1995) *Blood*, 86:1540-1547.
- De Boer, CJ et al. (1995) *Blood*, 86:2715-2723.
- Deininger, MW et al. (2000) *Blood*, 96:3343-56.
- Schlenk RF et al. (2008) *N Engl J Med*, 358:1909-1918.
- Gonzalez, D et al. (2003) *Leukemia*, 17:1051-1057.
- Gonzalez, D et al. (2003) *Leukemia*, 17:1398-1403.
- Ghia, P et al. (2007) *Leukemia*, 21:1-3.
- van Krieken, JH et al. (2007) *Leukemia*, 21:201-6.
- Evans, PAS et al. (2007) *Leukemia*, 21:207-214.
- Bruggemann, M et al. (2007) *Leukemia*, 21:215-221.
- Davi, F et al. (2008) *Leukemia*, 22:212-214.
- Döhner, H et al. (2010) *Blood*, 115:453-474.
- Huang, W et al. (1993) *Blood*, 82:1264-1269.
- Hughes, T et al. (2006) *Blood*, 108:28-37.
- Westbrook, CA et al. (1992) *Blood*, 80:2983-2990.
- Ralph, QM et al. (1993) *Blood*, 82:202-20.
- Juárez-Velázquez, MR et al. (2013) *Clinical Epidemiology of Acute Lymphoblastic Leukemia - From the Molecules to the Clinic*, 193-235.
- Raimondi, S. (2007) *Atlas Genet Cytogenet Oncol Haematol*, 11(4):328-339.
- Vardi, A et al. (2015) *Clin Cancer Res*, 22(1):167-174.
- Tan, BT et al. (2008) *J Mol Diag*, 10(6):502-512.
- González, D et al. (2007) *Blood*, 110:3112-3121.
- Langerak AW et al. (2007) *Exp Opin Med Diag*, 1(4):451-461.
- Arcila, ME et al. (2019) *J Mol Diag*, 2: 330-341.
- Campo, E et al. (2011) *Blood*, 117(19): 5019-5032.
- Smirnova, SY et al. (2016) *Acta naturae*, 8(4):100-109.
- Szczepanski, T et al. (2001) *Leukemia*, 15:1415-1423.
- Szczepanski, T et al. (1998) *Leukemia*, 12:1081-1088.
- Beishuizen, A et al. (1994) *Leukemia*, 8(12):2228-36.
- Tümkeya T et al. (2001) *Leukemia*, 15:121-127.
- Felix, CA et al. (1990) *J Clin Oncol*, 8(3):431-42.
- Rosenquist R et al. (2017) *Leukemia*, 31:1477-1481.
- Arons, E et al. (2011) *Blood*, 117(18): 4844-4851.
- Lai, R et al. (2006) *Modern Pathology*, 19:1498-1505.
- Srouf SA et al. (2017) *Br J Haematol*, 177(2): 331.
- Ohshima, K et al. (1990) *Hematol Oncol*, 8(2):111-8.
- van Dongen, JJM et al. (2003) *Leukemia*, 17, 2257-2317.

028 RevC July2020

Invivoscribe® is dedicated to Improving Lives with Precision Diagnostics® worldwide by providing high quality, reliable, cutting-edge tools for molecular biology and molecular diagnostics.

IdentiClone® Assays Gel/ABI

- » CE-IVD
- » BIOMED-2 design
- » Assays for B- and T-cell clonality assessment & Somatic Hypermutation (SHM) Assay
- » High sensitivity
- » Design supports low or high throughput
- » Easy interpretation

LymphoTrack® Dx Assays NGS

- » CE-IVD
- » One-step PCR for library generation
- » Identify, track, and assess mutation status of B- and T-cell gene rearrangements
- » Sequence amplicons from any LymphoTrack Dx kit together
- » Available for Illumina® MiSeq® and Thermo Fisher Scientific® Ion S5™ and PGM™ platforms
- » Bioinformatics software included for easy analysis and interpretation